drugset / Trial / NCT00664846

Standard Medical Management in Secondary Prevention of Ischemic Stroke in China

NCT00664846

Completed 4000 enrolled Peking Union Medical College Hospital
RandomizedParallel-groupOpen-labelPrevention

Summary

The purposes of the study are to analyse the cross-section data of secondary stroke prevention in China and to carry out a standard medical management including medicine and interactive education program,and to evaluate the efficacy and safety of the standard medical management in secondary stroke prevention.

Timeline

Start
2008-04
Primary completion
2010-12
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Background Acarbose Unknown 50 mg
Background Amlodipine Other / unclassified 5 mg
Background Aspirin Small molecule 75 mg
Background Aspirin Small molecule 150 mg
Background Atorvastatin Small molecule 20 mg
Background Benazepril Unknown 10 mg
Background Clopidogrel Small molecule 75 mg
Background Glipizide Small molecule 5 mg
Background Indapamide Small molecule 2.5 mg
Background Metformin Small molecule
Background Nifedipine Other / unclassified 30 mg
Background Simvastatin Small molecule 20 mg
Background Valsartan Small molecule 80 mg

Indications